CTSA and hepatocellular carcinoma: Second, the number of participants recruited in the validation cohorts remained small and the male–female ratio of HCC patients (> 4:1) differed from the real-world data (2.44:1)1, thus, the results should be interpreted with caution and further evaluation for AKR1B10 and CTSA are necessary in larger independent clinical cohorts.